TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16918945

Group type: EXPERIMENTAL
Intervention: Glucocorticoid plus mineralocorticoid hormone replacement
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 15190719

Group type: EXPERIMENTAL
Intervention: Digital clock for temporal information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overflow tank for spatial information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Static displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: Animated displays
Number of subjects: 0
Study: 10911825

Group type: EXPERIMENTAL
Intervention: Stinging nettle leaf (Urtica dioica) applied daily for one week
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo, white deadnettle leaf (Lamium album)
Number of subjects: 27
Study: 9304948

Group type: EXPERIMENTAL
Intervention: Inspiring Psychological Nursing
Number of subjects: 176

Group type: COMPARATOR
Intervention: General medical care (Control)
Number of subjects: 176
Study: 8375461

Group type: EXPERIMENTAL
Intervention: Normal respiratory rate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 25% slower respiratory rate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 25% faster respiratory rate
Number of subjects: 9
Study: 3535980

Group type: EXPERIMENTAL
Intervention: Applied relaxation training (ART) taught during one session using participant demonstration, written instructions, taped instructions, or a combination of all three; practice at home encouraged.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Applied relaxation training (ART)
Number of subjects: 0
Study: 30394148

Group type: EXPERIMENTAL
Intervention: Pioglitazone plus phototherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo plus phototherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 28295581

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (initial dose: 0.2 mg/kg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Immediate-release tacrolimus (initial dose: 0.1 mg/kg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus
Number of subjects: 25

Group type: COMPARATOR
Intervention: Immediate-release tacrolimus
Number of subjects: 25
Study: 26610843

Group type: EXPERIMENTAL
Intervention: Supplemental vibrational force (AcceleDent) 20-minutes/day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-functional (sham) device
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fixed-appliances only
Number of subjects: 81
Study: 23569311

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg with docetaxel 100 mg/m(2) and trastuzumab 8 mg/kg loading dose followed by 6 mg/kg, administered every 3 weeks
Number of subjects: 424

Group type: COMPARATOR
Intervention: Docetaxel 100 mg/m(2) and trastuzumab 8 mg/kg loading dose followed by 6 mg/kg without bevacizumab, administered every 3 weeks
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg with docetaxel and trastuzumab
Number of subjects: 424

Group type: COMPARATOR
Intervention: Docetaxel and trastuzumab without bevacizumab
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing therapy
Number of subjects: 424
Study: 21483158

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 mg atorvastatin
Number of subjects: 40
Study: 19500335

Group type: EXPERIMENTAL
Intervention: Infliximab (anti-TNF therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RA patients
Number of subjects: 0
Study: 17031005

Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: 4-Day Food Records (4DFR)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Demographic and behavioral factors (smoking, gender, education)
Number of subjects: 399
Study: 14699862

Group type: EXPERIMENTAL
Intervention: L dose group (8 mumol Fe/kg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: H dose group (12 mumol Fe/kg)
Number of subjects: 84
Study: 10820297

Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude upper cervical adjustment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 36
Study: 8893144

Group type: EXPERIMENTAL
Intervention: Oral calcitriol (0.25 microgram/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Uraemic patients
Number of subjects: 25
Study: 1709686

Group type: COMPARATOR
Intervention: Pelvic radiotherapy (RT; arm A)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by pelvic radiotherapy (CT + RT; arm B) - three cycles of chemotherapy (BOMP: bleomycin, vincristine, mitomycin, and cisplatin) followed by RT
Number of subjects: 107
Study: 6402369

Group type: EXPERIMENTAL
Intervention: Oral MESNA (840 mg/m2 at 0 hr, 4 hr, and 8 hr p.i.)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional prophylactic measures (raised fluid intake and forced diuresis)
Number of subjects: 45
Study: 31682230

Group type: EXPERIMENTAL
Intervention: HVTT-PVTT score (differentiating < 3 and ≥ 3 points)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Cox regression model and CART algorithm
Number of subjects: 869
Study: 28535076

Group type: EXPERIMENTAL
Intervention: Cingal (4 mL, 88 mg hyaluronic acid plus 18 mg triamcinolone hexacetonide)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Monovisc (4 mL, 88 mg hyaluronic acid)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Saline (4 mL, 0.9%)
Number of subjects: 368
Study: 26862988

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 24804695

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (intramuscular testosterone undecanoate for 40 weeks)
Number of subjects: 88
Study: 23122652

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg per day (IV)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Interferon beta 1a 44 μg (SC)
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 581

Group type: COMPARATOR
Intervention: Interferon beta 1a
Number of subjects: 581
Study: 20573586

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) in CP+NGT group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test (IVGTT) in CP+NGT group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) in CP+IGT group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test (IVGTT) in CP+IGT group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) in CP+DM group
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous Glucose Tolerance Test (IVGTT) in CP+DM group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oral Glucose Tolerance Test (OGTT) in healthy subjects
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous Glucose Tolerance Test (IVGTT) in healthy subjects
Number of subjects: 32
Study: 18075302

Group type: EXPERIMENTAL
Intervention: PDGF BB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib mesylate (Gleevec)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Malignant ascites
Number of subjects: 0
Study: 15625138

Group type: EXPERIMENTAL
Intervention: 20 mg oral furosemide daily for 5 days with oral potassium supplementation
Number of subjects: 264

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 264
Study: 12163426

Group type: EXPERIMENTAL
Intervention: valsartan 80 mg/d
Number of subjects: 332

Group type: COMPARATOR
Intervention: amlodipine 5 mg/d
Number of subjects: 332
Study: 10492056

Group type: EXPERIMENTAL
Intervention: Tamsulosin in patients with renal dysfunction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with alpha1‐AGP levels over 0.9 mg/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with alpha1‐AGP levels less than 0.7 mg/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0
Study: 8942423

Group type: EXPERIMENTAL
Intervention: Vitamins C and E (1 g ascorbic acid and 400 mg dl-alpha-tocopheryl acetate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vitamin E (400 mg dl-alpha-tocopheryl acetate)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vitamin C (1 g ascorbic acid)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vitamins C and E
Number of subjects: 20
Study: 2048459

Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral mood management training
Number of subjects: 52
Study: 6763373

Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate (250, 500, or 1000 micrograms)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31322601

Group type: EXPERIMENTAL
Intervention: Stainless-steel pediatric crowns (SCC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Compomer filling
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: SCC
Number of subjects: 68
Study: 29242039

Group type: EXPERIMENTAL
Intervention: Rinse A (1.5% KOX, pH 4.5)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rinse B (1.5% KOX, pH 7.0)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rinse C (2.0% KOX, 45 ppm fluoride, pH 4.5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo rinse (no KOX or fluoride, pH 4.5)
Number of subjects: 0
Study: 26635263

Group type: EXPERIMENTAL
Intervention: Remote monitoring (n=30)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional hospital monitoring (n=52)
Number of subjects: 82
Study: 24521353

Group type: EXPERIMENTAL
Intervention: WPC-RUTF
Number of subjects: 0

Group type: COMPARATOR
Intervention: P-RUTF
Number of subjects: 0
Study: 23118720

Group type: EXPERIMENTAL
Intervention: 30% FFA suppositories
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 30
Study: 19440265

Group type: EXPERIMENTAL
Intervention: PUP law enforcement and reducing minors' access to commercial sources of tobacco
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reducing minors' access to commercial sources of tobacco
Number of subjects: 24
Study: 17878744

Group type: EXPERIMENTAL
Intervention: 2 mg of alprazolam orally
Number of subjects: 24
Study: 14716761

Group type: EXPERIMENTAL
Intervention: Capecitabine at 1250 mg/m² twice daily on Days 2-15 and irinotecan at 300 mg/m² on Day 1 (Arm A)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Capecitabine at 1250 mg/m² twice daily on Days 2-15 and irinotecan at 150 mg/m² on Days 1 and 8 (Arm B)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Lower doses of capecitabine (1000 mg/m²) and irinotecan (Arm A: 240 mg/m²; Arm B: 120 mg/m²)
Number of subjects: 140
Study: 11124289

Group type: EXPERIMENTAL
Intervention: Emedastine 0.05%
Number of subjects: 97

Group type: COMPARATOR
Intervention: Levocabastine 0.05%
Number of subjects: 97
Study: 9282256

Group type: EXPERIMENTAL
Intervention: Hypocaloric balanced diet (HCBD)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Protein sparing modified fast diet (PSMF)
Number of subjects: 55
Study: 7950459

Group type: EXPERIMENTAL
Intervention: 3 HRZ2 6 HR2 (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3 HR/3 HR2/6 H2 (control group)
Number of subjects: 0
Study: 3514082

Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg daily, with option to reduce to 10 mg at week 4 or 8)
Number of subjects: 2035

Group type: COMPARATOR
Intervention: Naproxen (750 mg daily, with option to reduce to 500 mg at week 4 or 8)
Number of subjects: 2035
Study: 3345774

Group type: EXPERIMENTAL
Intervention: Adenosine (doses of 20, 30, 40, 50, 60, 80 and 100% of the maximum tolerable dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Citric acid (concentrations of 1‐100 mM)
Number of subjects: 6
Study: 30387374

Group type: EXPERIMENTAL
Intervention: Critical Power (CP) derived from self-paced time-trial prediction trials
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Functional Threshold Power (FTP)
Number of subjects: 12
Study: 28195948

Group type: EXPERIMENTAL
Intervention: Zofenopril plus acetyl salicylic acid
Number of subjects: 265

Group type: COMPARATOR
Intervention: Ramipril plus acetyl salicylic acid
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Zofenopril
Number of subjects: 265

Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 265
Study: 25180525

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 657

Group type: COMPARATOR
Intervention: White girls
Number of subjects: 657
Study: 23343329

Group type: EXPERIMENTAL
Intervention: Mobile-phone based assessment via text-messages or Android application
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mobile-phone based assessment
Number of subjects: 24
Study: 21973110

Group type: EXPERIMENTAL
Intervention: Structured 10-session psychosocial support group intervention
Number of subjects: 361
Study: 18535768

Group type: EXPERIMENTAL
Intervention: Quality measures based on CONSORT statement and additional check items
Number of subjects: 13
Study: 17071213

Group type: EXPERIMENTAL
Intervention: Group behavior therapy (BT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Group supportive therapy (ST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naturalistic waiting period
Number of subjects: 24
Study: 12576845

Group type: EXPERIMENTAL
Intervention: Phenol sclerotherapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Hydrocelectomy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 67
Study: 11093990

Group type: EXPERIMENTAL
Intervention: Multimodal clinical care algorithm (Group I)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard balanced outpatient anesthetic with ondansetron 4 mg (Group II)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo (Group III)
Number of subjects: 139
Study: 9373420

Group type: EXPERIMENTAL
Intervention: Cognitive therapy and maintenance cognitive therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Antidepressants and maintenance antidepressants
Number of subjects: 75

Group type: COMPARATOR
Intervention: Antidepressants and maintenance cognitive therapy
Number of subjects: 75
Study: 1616387

Group type: EXPERIMENTAL
Intervention: Enteral feeding
Number of subjects: 98

Group type: COMPARATOR
Intervention: Total parenteral nutrition (C)
Number of subjects: 98
Study: 3987804

Group type: EXPERIMENTAL
Intervention: Enteric-coated pellets of erythromycin base administered 1 hour before breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Enteric-coated tablets
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enteric-coated pellets of erythromycin base during a non-standardized breakfast
Number of subjects: 24
Study: 29770553

Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Number of subjects: 101

Group type: COMPARATOR
Intervention: Implementation intention
Number of subjects: 101
Study: 27759625

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg single dose) plus amoxicillin (1g twice daily), bismuth (240 mg), and omeprazole (20 mg) for 14 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gemifloxacin-containing therapy
Number of subjects: 120
Study: 24188146

Group type: EXPERIMENTAL
Intervention: Acculturation measures in English
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Acculturation measures in Spanish
Number of subjects: 574

Group type: COMPARATOR
Intervention: Acculturation measures (both languages)
Number of subjects: 574
Study: 21949432

Group type: EXPERIMENTAL
Intervention: Daily low‐pressure pulsatile lavage treatment with 1 L of normal saline at 11 psi of pressure
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 28
Study: 20470671

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg in combination with concurrent radiotherapy (RT) +/‐ concomitant cisplatin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gefitinib and RT with concurrent cisplatin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline S‐VEGF levels
Number of subjects: 15
Study: 17868194

Group type: EXPERIMENTAL
Intervention: +TRP
Number of subjects: 16

Group type: COMPARATOR
Intervention: -TRP
Number of subjects: 16
Study: 15998268

Group type: EXPERIMENTAL
Intervention: Full-mouth ultrasonic debridement (Fm-UD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Quadrant scaling/root planing (Q-SRP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ultrasonic re-treatment
Number of subjects: 41

Group type: COMPARATOR
Intervention: Hand instrumentation re-treatment
Number of subjects: 41
Study: 12921607

Group type: EXPERIMENTAL
Intervention: Ordinary treatment of chronic gastritis (plan A)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Functional dyspepsia treatment (plan B)
Number of subjects: 214
Study: 11094001

Group type: EXPERIMENTAL
Intervention: 7.5% hypertonic saline (HS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 40
Study: 9010701

Group type: EXPERIMENTAL
Intervention: Morphine (20 or 30 mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Codeine (75 or 100 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 1488756

Group type: EXPERIMENTAL
Intervention: Postremission therapy without prednisolone (PSL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postremission therapy with prednisolone (PSL)
Number of subjects: 30
Study: 2880467

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29703714

Group type: EXPERIMENTAL
Intervention: Generalized, exclusively email-based prompts
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Personalized knowledge broker providing support through phone- and email-based check-ins
Number of subjects: 38
Study: 28106552

Group type: EXPERIMENTAL
Intervention: Kirtan Kriya meditation (KK)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Music listening (ML)
Number of subjects: 60
Study: 25592742

Group type: EXPERIMENTAL
Intervention: Souvenaid™ (125 ml/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 23935162

Group type: EXPERIMENTAL
Intervention: Blinded-independent central review (BICR)
Number of subjects: 722
Study: 21931077

Group type: EXPERIMENTAL
Intervention: Combined home health education (HHE) plus trained general practitioner (GP)
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Home health education (HHE) only
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Trained GP only
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Usual care (no intervention)
Number of subjects: 1341
Study: 19145932

Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes (HbA1c < 7.5%)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Patients with type 2 diabetes (HbA1c ≥ 7.5%)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 58
Study: 16357116

Group type: EXPERIMENTAL
Intervention: Org 25969 0.5 mg kg(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Org 25969 4.0 mg kg(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Org 25969 (various doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Org 25969 (2-4 mg kg(‐1))
Number of subjects: 30
Study: 12813331

Group type: EXPERIMENTAL
Intervention: Low-dose unfractionated heparin (UFH) 5,000 U every 8 hours
Number of subjects: 119

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 119
Study: 10540135

Group type: EXPERIMENTAL
Intervention: Faecal occult blood screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-screened)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stage A tumours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Well or moderately differentiated tumours
Number of subjects: 0
Study: 8941507

Group type: EXPERIMENTAL
Intervention: Coca chewing (15 g)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (sugar-free chewing gum)
Number of subjects: 12
Study: 1685100

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of vecuronium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of vecuronium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of vecuronium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of vecuronium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anesthetized state (baseline)
Number of subjects: 40
Study: 6127039

Group type: EXPERIMENTAL
Intervention: D-2343 (0.21-6.3 micrograms kg-1 min-1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: QH 25 (0.25, 0.75, and 2.25 mg orally)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Terbutaline (0.07-2.1 micrograms kg-1 min-1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Salbutamol (2, 6, and 18 mg orally)
Number of subjects: 8
Study: 30796338

Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise and resistance training (aerobic exercise thrice weekly and resistance training twice weekly for 12 weeks)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise and resistance training
Number of subjects: 47
Study: 27718533

Group type: EXPERIMENTAL
Intervention: Multiple-component structured manualized group intervention (MGI)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Single-component group intervention (SGI)
Number of subjects: 170
Study: 25759565

Group type: EXPERIMENTAL
Intervention: Udenafil 200 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Concurrent administration of Udenafil and Dapoxetine
Number of subjects: 23
Study: 24529669

Group type: EXPERIMENTAL
Intervention: Atracurium (20% of ED95 × kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study: 20828895

Group type: EXPERIMENTAL
Intervention: Bone filter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bone fragment (rongeur)
Number of subjects: 30
Study: 18579368

Group type: EXPERIMENTAL
Intervention: BPPV with volume targeting
Number of subjects: 12

Group type: COMPARATOR
Intervention: BPPV with usual ventilator settings
Number of subjects: 12
Study: 17159457

Group type: EXPERIMENTAL
Intervention: Quetiapine monotherapy, 300 or 600 mg/day
Number of subjects: 542

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study: 15019892

Group type: EXPERIMENTAL
Intervention: Statin therapy at the time of hospital discharge
Number of subjects: 0